The reasons for the discrepancy between preclinical animal results and clinical human trial data are debated in the nanomedicine community, but we believe that the primary reasons are the less pronounced EPR effect in and the heterogeneity of human tumors as well as the intrinsic or acquired resistance to monotherapy.
A law on biobanks was drafted and in that context the use of existing data was debated.
It's a lot like the global warming data being debated while the ice caps melt before our eyes.
In this regard, the data in literature are debated and do not clarify whether denial of illness is a psychosis-like symptom or rather a rigid and disadaptive defense mechanism helping patients to protect themselves by anxiety and depression [ 26, 31] and to avoid treatments [ 89] or negative emotions [ 22, 23].
Nevertheless, the validity of the data on US boys has been debated, and an expert panel has recently concluded that, the currently available data are insufficient in quality and quantity to confirm a change in pubertal timing in US boys [16].
Gender differences in benefit from an early invasive strategy have been debated and data are conflicting for preforming PCI in ACS patients.
16– 18 However, the agreement between RBT and GAT readings in children is debated, and more data are necessary to assess the differences, including data at various IOPs.
However, correlation between enhancement and clinical findings is debated, and limited data are available regarding the reliability of enhancement findings.
The role of HER2 in ductal breast carcinoma in situ (DCIS) is debated and recent data have suggested that HER2 is mainly related to in situ recurrences.
Even though this hypothesis has been considered true both from first principles and data, it has been debated (Studer and Robinson-Rechavi, 2009), and was recently challenged with counter evidence.
